share_log

Processa Pharma Analyst Ratings

Benzinga ·  Nov 18, 2023 02:37
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/17/2023 Maxim Group Downgrades Buy → Hold
04/04/2023 814.29% Benchmark $9 → $4 Maintains Speculative Buy
04/03/2023 585.71% Oppenheimer $5 → $3 Maintains Outperform
01/12/2023 1042.86% Maxim Group $9 → $5 Maintains Buy
04/19/2022 1957.14% Maxim Group → $9 Initiates Coverage On → Buy
08/03/2021 4471.43% Oppenheimer → $20 Initiates Coverage On → Outperform
08/02/2021 4471.43% Oppenheimer → $20 Initiates Coverage On → Outperform
10/28/2020 2642.86% Craig-Hallum → $12 Initiates Coverage On → Buy

What is the target price for Processa Pharma (PCSA)?

The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by Maxim Group on November 17, 2023. The analyst firm set a price target for $0.00 expecting PCSA to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Processa Pharma (PCSA)?

The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by Maxim Group, and Processa Pharma downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Processa Pharma (PCSA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.

Is the Analyst Rating Processa Pharma (PCSA) correct?

While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Processa Pharma (PCSA) is trading at is $0.44, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment